WO2014022867A1 - Cathéters à ballons multiples endovasculaires à diffuseur optique pour le traitement de sténoses vasculaires - Google Patents

Cathéters à ballons multiples endovasculaires à diffuseur optique pour le traitement de sténoses vasculaires Download PDF

Info

Publication number
WO2014022867A1
WO2014022867A1 PCT/US2013/053671 US2013053671W WO2014022867A1 WO 2014022867 A1 WO2014022867 A1 WO 2014022867A1 US 2013053671 W US2013053671 W US 2013053671W WO 2014022867 A1 WO2014022867 A1 WO 2014022867A1
Authority
WO
WIPO (PCT)
Prior art keywords
balloon
catheter
vascular
lumen
vessel
Prior art date
Application number
PCT/US2013/053671
Other languages
English (en)
Other versions
WO2014022867A8 (fr
Inventor
Richard Noddin
Yem Chin
Ed Sinofsky
Paul Scopton
Christopher PIERSON
Ronald UTECHT
Original Assignee
Alumend, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alumend, Llc filed Critical Alumend, Llc
Publication of WO2014022867A1 publication Critical patent/WO2014022867A1/fr
Publication of WO2014022867A8 publication Critical patent/WO2014022867A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1011—Multiple balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/1204—Type of occlusion temporary occlusion
    • A61B17/12045—Type of occlusion temporary occlusion double occlusion, e.g. during anastomosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12181—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
    • A61B17/12195—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices comprising a curable material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/94—Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
    • A61F2/945—Stents retaining their form, i.e. not being deformable, after placement in the predetermined place hardenable, e.g. stents formed in situ
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
    • A61B18/22—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
    • A61B18/24—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor with a catheter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22038—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for with a guide wire
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B2018/1807—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using light other than laser radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/005—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements using adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/0058—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements soldered or brazed or welded
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1011—Multiple balloon catheters
    • A61M2025/1013—Multiple balloon catheters with concentrically mounted balloons, e.g. being independently inflatable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1079—Balloon catheters with special features or adapted for special applications having radio-opaque markers in the region of the balloon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/104—Balloon catheters used for angioplasty

Definitions

  • the present disclosure relates to catheters and, more particularly, to endovascular multi-balloon catheters having an optical diffuser for treatment of vascular stenoses.
  • Vascular plaque causes several medical conditions, including but not limited to, coronary artery disease, carotid artery disease, and peripheral artery disease, resulting in hypertension, ischemic injury, stroke, or myocardial infarction and sometimes death.
  • vascular smooth muscle cells proliferate at a low rate, approximately less than 0.1 percent per day.
  • VSMC cells in the vessel walls exist in a contractile phenotype characterized by eighty to ninety percent of the cell cytoplasmic volume occupied with the contractile apparatus. Endoplasmic reticulum, Golgi, and free ribosomes are few and are located in the perinuclear region.
  • Extracellular matrix surrounds the VSMC, and is rich in heparin- like glycosylaminoglycans, which are believed to be responsible for maintaining smooth muscle cells in the contractile phenotypic state.
  • Atherogenesis is the developmental process of atheromatous plaques, resulting in atherosclerotic narrowing of the cardiovasculature over time.
  • the build-up of an atheromatous plaque is a slow process, developed over a period of several years through a complex series of cellular events occurring within the arterial wall, and in response to a variety of local vascular circulating factors.
  • Atheromatous plaques form in the arterial tunica intima, a region of the vessel wall located between the endothelium and the tunica media. The bulk of these lesions are made of excess fat, collagen, and elastin.
  • Stenosis is a late event, which may never occur and is often the result of repeated plaque rupture and healing responses, not just the atherosclerotic process by itself.
  • Such vascular stenoses are alternatively referred to as vascular lesions.
  • Intracellular micro-calcifications form within the VSMC of the surrounding muscular layer, specifically in the muscle cells adjacent to the atheromas. As the atherosclerotic diseases progresses, these VSMC become abnormally proliferative, secreting substances (e.g., growth factors, tissue-degradation enzymes and other proteins). In time, as cells die, this leads to extracellular calcium deposits between the muscular wall and outer portion of the atheromatous plaques. The outer, older portions of the plaque become more calcific, less metabolically active and more physically rigid over time.
  • Two plaque types can be distinguished, namely: (a) fibro- lipid / fatty plaques; and (b) fibrous / calcified plaques.
  • the fibro-lipid (fibro-fatty) plaque is characterized by an accumulation of lipid-laden cells underneath the intima of the arteries, typically without narrowing the lumen due to compensatory expansion of the bounding muscular layer of the artery wall. Beneath the endothelium there is a "fibrous cap” covering the atheromatous "core” of the plaque.
  • the core consists of lipid-laden cells (macrophages and smooth muscle cells) with elevated tissue cholesterol and cholesterol ester content, fibrin, proteoglycans, collagen, elastin, and cellular debris.
  • the central core of the plaque usually contains extracellular cholesterol deposits (released from dead cells), which form areas of cholesterol crystals with empty, needle-like clefts.
  • plaques At the periphery of the plaque are younger "foamy" cells and capillaries. These type of plaques are sometimes referred to as vulnerable plaques, and usually produce the most damage to the individual when they rupture, often leading to fatal myocardial infarction when present within the coronary arteries.
  • the fibrous plaque is also localized under the intima, within the wall of the artery resulting in thickening and expansion of the wall and, sometimes, spotty localized narrowing of the lumen with some atrophy of the muscular layer.
  • the fibrous plaque contains collagen fibers (eosinophilic), precipitates of calcium (hematoxylinophilic) and, rarely, lipid-laden cells. Atheromas within the vessel wall are soft and fragile with little elasticity.
  • calcification deposits after they have become sufficiently advanced, are partially visible on coronary artery computed tomography or electron beam tomography (EBT) as rings of increased radiographic density, forming halos around the outer edges of the atheromatous plaques, within the artery wall.
  • EBT electron beam tomography
  • CT computed tomography
  • greater than 130 units on the Hounsfield scale has been the radiographic density usually accepted as clearly representing tissue calcification within arteries.
  • a carotid intima- media thickness scan (CIMT can be measured by B-mode ultrasonography) measurement has been recommended by the American Heart Association as the most useful method to identify atherosclerosis.
  • IVUS Intravascular ultrasound
  • OCT optical coherence tomography
  • Angiography since the 1960s, has been the traditional way of evaluating atheroma. However, angiography is only motion or still images of dye mixed with the blood within the arterial lumen and do not directly visualize atheroma. Rather, the wall of arteries, including atheroma with the arterial wall, generally remain invisible, with only limited shadows which define their contoured boundaries based upon x-ray absorption. The limited exception to this rule is that with very advanced atheroma, with extensive calcification within the wall, a halo-like ring of radiodensity can be seen in older patient, especially when arterial lumens are visualized end-on. On cine-floro, cardiologists and radiologists typically look for these calcification shadows to recognize arteries before they inject any contrast agent during angiograms.
  • Interventional vascular procedures such as percutaneous transluminal angioplasty (PTA) for peripheral vascular disease and percutaneous transluminal coronary angioplasty (PTCA) for coronary artery disease, are typically performed using an inflatable balloon dilatation catheter to restore increased luminal diameter at the vascular lesion.
  • PTA percutaneous transluminal angioplasty
  • PTCA percutaneous transluminal coronary angioplasty
  • the dilatation catheter is positioned within the blood vessel at the location of the narrowing caused by the lesion, and the balloon is expanded with inflation fluid to dilate the vessel lumen.
  • a second balloon catheter which carries and deploys an expandable metal stent which serves to maintain vessel patency.
  • inflammatory cells adhere to the site of vascular injury. Within three to seven days post-injury, inflammatory cells have migrated to the deeper layers of the vessel wall. In animal models employing either balloon injury or stent implantation, inflammatory cells may persist at the site of vascular injury for at least thirty days. Inflammatory cells therefore are present and may contribute to both the acute and chronic phases of restenosis.
  • Restenosis can occur following coronary artery bypass graft surgery (CABG), endarterectomy, heart transplantation, and with increased frequency following percutaneous balloon angioplasty (PTA and PTC A), atherectomy, laser ablation or endovascular stenting.
  • CABG coronary artery bypass graft surgery
  • PTA and PTC A percutaneous balloon angioplasty
  • atherectomy laser ablation
  • endovascular stenting up to one-third of patients receiving a revascularization procedure will redevelop artery- blockage (i.e., restenosis) within a little as six months after treatment. Restenosis is ultimately responsible for recurrence of symptoms (or death), often requiring repeat revascularization surgery.
  • an atherectomy procedure In the event that an atherectomy procedure is required, the interventional physician must first deploy an embolic protection device (EPD) within the vessel being treated at a location which is distal (i.e., downstream relative to blood flow) to the atherectomy treatment site.
  • EPD embolic protection device
  • plaque particulates which are dislodged by the atherectomy device can occasionally escape the EPD and travel downstream within the vasculature causing a stroke, heart attack or otherwise permanently compromise distal vascular blood flow.
  • the use of atherectomy devices produces substantial trauma to the blood vessel, and can produce serious complications such as thrombosis, as well as poor vascular healing response leading to premature restenosis.
  • vascular stent implants Over the past three decades, interventional revascularizations are often followed by the deployment of vascular stent implants. Unfortunately, these devices are sometimes prone to produce thrombus which can embolize causing strokes, myocardial infarct, and the like. Additionally, stents may tend to fatigue over time, leading to strut fracture which causes further damage to adjacent vascular tissue, as well as increased risk of severe thrombosis complications.
  • stents in certain peripheral vascular such as the superficial femoral artery (SFA) which decends below the waist to the knees, is particularly poorly suited for stenting, in view of the substantial forces which act upon the SFA during walking as well as sitting, such as substantial vessel / stent elongation, vessel / stent compression and vessel / stent torsional motion.
  • SFA superficial femoral artery
  • Much of the VSMC phenotypic dedifferentiation after arterial injury mimics that of neoplastic cells (i.e., abnormal proliferation, growth-regulatory molecule and protease secretion, migration and basement invasion).
  • stents that are permanently implanted in coronary or peripheral vessels and release (elute) drugs that inhibit or prevent cell proliferation and therefore prevent the narrowing created by VSMC proliferation.
  • drug eluting stents reduce VSMC proliferation and restenosis on the one hand, they also prevent recovery of an endothelial cell monolayer for an extended period of time (e.g., several months or longer), thereby making the vessel wall thrombogenic for an extended period.
  • the resulting clinical outcome is late clotting of drug-eluting stents (DES), resulting in chronic health risks, such as late-stage thrombosis.
  • DES drug-eluting stents
  • anticoagulant and antiplatelet drugs e.g., aspirin and Plavix
  • endothelial cell recovery and vessel healing will happen within this one year window.
  • anticoagulant and antiplatelet drugs e.g., aspirin and Plavix
  • increasing numbers of patients receiving DES implants are being required to continue various platelet anti-aggregation, anti-coagulant therapy for several years if not indefinitely, with enormous additional healthcare cost and with considerable future health complications and patient inconvenience.
  • Balloon catheters that facilitate passive diffusion of the pharmacological agent to reach only the innermost layers of the artery wall include dual (i.e., double) balloon occlusion catheters, channel balloon catheters, microporous balloon catheters and hydrogel balloon catheters.
  • Dual-balloon occlusion catheters have an infusion port separated by two balloons that expand under low-pressure inflation to a predetermined diameter. When inflated, the balloons isolate a treatment zone within the vascular treatment site, enabling the physician to infuse a specified fluid which contains the therapeutic agent and maintain a high local concentration compared to systemic infusion.
  • the fluid infused may contain a pharmaceutical agent, or an infusion of cell / gene therapy materials carried in suspension, which can then be introduced through a port into the retaining space created between the dual, inflated balloons.
  • Early dual- occlusion balloon system for drug delivery are taught, for example, by U.S. Patent No. 4,636,195 to Wolinsky and U.S. Patent No.
  • 4,824,436 to Wolinsky utilize a dual-balloon arrangement located at the distal end of the catheter, with the balloons being longitudinally spaced apart, including a proximal occlusion balloon and a distal occlusion balloon.
  • the proximal and distal balloons are located on opposite sides of a vascular lesion, and a space is defined therebetween.
  • the occlusion balloons are inflated, the desired therapeutic agent can be infused through another lumen provided in the catheter to enter the occluded vascular space.
  • the dual balloon system creates a cylindrical space for infusion of a drug which is isolated from blood flow through the artery or vein. This system offers a safety advantage, since relatively minor damage to the vessel intima and media results from the low occlusion balloon pressures.
  • Helical or spiral-shaped balloon catheters are modified dual-balloon structures having a coil-shaped balloon wrapped around a perfusion channel forming a through-lumen to permit passive perfusion of blood flow while the helical balloon is inflated into contact with inner surface of the vessel wall.
  • the proximal and distal ends of the helical balloon are designed to occlude the region of the artery which overlies the balloon structure, while providing a closed helical space into which therapeutic fluid can be introduced through an infusion port.
  • An exemplary helical balloon catheter suitable for localized vascular drug delivery is described in U.S. Patent No. 5,554,119 to Harrison et al., which corresponds to the DISPATCHTM catheter developed and manufactured by SciMed Life Systems, Inc.
  • this passive blood perfusion feature supports longer inflation times, giving the therapeutic fluid more time to interact with the vessel wall.
  • both helical and dual-balloon occlusion catheters may suffer some compromise in the event of significant branch vessels which intersect with the vascular treatment site of the parent vessel, careful positioning of the device may be sufficient to block alternative blood flow conduits.
  • Hydrogel-coated balloons are angioplasty balloon catheters whose exterior is coated with an adsorbent polymer-based coating which has been saturated or loaded with a selected therapeutic agent. Following balloon inflation, the drug- impregnated polymer physically contacts with the vessel wall. Comparatively, the local therapeutic drug dose is required to be significantly higher on the coated surface of this device relative to the levels needed to support delivery within a confined cylindrical space provided by a double or spiral balloon catheter. For example, histological analysis of artery wall segments after hydrogel balloon delivery of a viral-mediated ⁇ -galactosidase reporter gene showed gene expression predominantly in medial cells, suggesting this as a method for penetrating beneath the intimal cell layer.
  • interventional revascularization therapies for patients requiring PTA or PTCA procedures, but without the necessity of having to implant a prosthetic stent which may restenose or otherwise fracture due to prolonged fatigue at certain high-stress anatomy of the vasculature, or which may fail to properly heal due to complications associated with pharmaceutical agents delivered by DES implants and / or the polymeric coatings used on the DES implants to provide the desired release kinetics of therapeutic agents.
  • interventional revascularization therapies which can reliably restore vessel patency to both arteries and veins, including previous CABG patients whose sapphenous vein bypass grafts have become occluded over time.
  • the present disclosure accordingly is directed to a system for providing a more comprehensive, universally-applicable vascular intervention which enables treatment of a broader category of patients suffering from atherosclerotic disease.
  • the present disclosure includes an interventional catheter which controllably delivers certain chemical formulations, based upon various naphthalimide-based carrier solutions as disclosed in more detail in U.S. Patent No. 7,514,399 to Utecht et al. and U.S. Provisional Application No. 61/679,365, entitled “Compositions and Methods of Using the Compositions for Plaque Softening,” filed on August 3, 2012, the disclosures of which are incorporated herein by reference.
  • the chemical formulations are locally infused by the catheter into the desired vascular treatment site in order to facilitate treatment of a vessel requiring revascularization (e.g., an artery or vein having narrowed luminal regions, such as stenoses restricting blood flow).
  • a vessel requiring revascularization e.g., an artery or vein
  • the present disclosure is intended to restore and maintain the vessel patency of stenosed vasculature, including treatment of vasculature lesions comprising atherosclerotic plaque which may or may not be calcified, and to effectively softens calcified plaque, thereby enabling pecutaneous transluminal angioplasty (e.g., PTA and PTCA) to be performed on the treated plaque in order to reestablish and maintain the desired vessel patency.
  • pecutaneous transluminal angioplasty e.g., PTA and PTCA
  • the present disclosure specifically contemplates use of these naphthalimide-based carrier solutions to enable adjunctive drug delivery of various therapeutic agents, which can be releasably tethered to the carrier solution to ensure diffusion of an effective dose of the desired therapeutic agent throughout the intramural space of the vascular wall (e.g., intima, media and adventitia), following which the agents are released into the vascular tissue to improve healing and inhibit restenosis following revascularization.
  • vascular wall e.g., intima, media and adventitia
  • naphthalimide-polyethylene glycol naphthalimide- PEG
  • the naphthalimide-polyethylene glycol (naphthalimide-PEG) composition may be a biocompatible, light-activated polyethylene- glycol (PEG) based solution with the viscosity of saline.
  • This naphthalimide-PEG composition is water-soluble and has a low molecular weight which enables diffusion through atherosclerotic plaque and calcium and into the vessel wall, including the media.
  • This naphthalimide-PEG composition is supplied in an 8ml vial containing 7ml of solution.
  • This naphthalimide-PEG composition can be activated at the vascular treatment site, such as by photoactivation, thereby cleaving off the naphthalimide molecules which are readily eliminated from the body.
  • the PEG linkers are photochemically produced as a reactive intermediate during release, and these PEG linkers will bind at their opposite active ends to available collagen protein naturally present within the numerous collagen fibrils which comprise the vascular wall tissue. As a result, the cross-linked collagen fibrils will be reinforced and stabilized.
  • NVS Natural Vascular Scaffolding
  • the ability to diffuse the NVS carrier solutions directly into all layers of the vessel e.g., arterial layers of intima, media, and adventitia
  • a tethered drug which becomes bio-available as a function of the rate of hydrolysis of the linker is believed to more effectively deliver drugs directly into the vascular tissue requiring therapy.
  • PTA balloon dilatation procedures are performed on patients using standard PTA catheters which include a dilatation balloon disposed at the distal end of the catheter.
  • the distal end of the PTA catheter is advanced to the vascular stenosis over a pre-advanced guidewire, and the dilatation balloon is positioned across the vascular stenosis or lesion (i.e., vascular blockage produced by plaque deposition which restricts blood flow).
  • the dilatation balloon is aligned with the vascular stenosis, it is inflated to compress the plaque against the vessel wall, thereby reestablishing the vessel lumen. Once the vessel lumen is restored, the PTA catheter is withdrawn from the patient.
  • the guidewire used during the PTA procedure is left in place such that it remains within the vessel, extending across the treated region of the vessel where the stenosis was dilated.
  • the present disclosure contemplates removal of the initial PTA catheter, and substitution with an NVS therapeutic catheter in place of a stent delivery catheter.
  • an NVS therapeutic catheter is introduced over the pre-advanced guidewire to position the distal end of the NVS catheter precisely at the region of the vessel previously treated by the PTA catheter.
  • FIG. 1 is an illustration of an exemplary catheter in accordance with various aspects of the disclosure
  • FIG. 2 is a cross-sectional view of the catheter along II-II of FIG. 1;
  • FIG. 3 is an illustration of a distal end of the catheter of
  • FIG. 1 A first figure.
  • FIG. 4 is an illustration of an exemplary light fiber for use with the catheter of FIG. 1;
  • FIG. 5 is a longitudinal cross sectional view of the distal portion of a balloon catheter assembly having multiple balloons in accordance with various aspects of the disclosure.
  • the NVS therapeutic catheter comprises a catheter shaft 110 incorporating five lumens 111, 112, 113, 114, and 115 extending longitudinally the majority of the length of the catheter shaft.
  • the entire catheter shaft measures approximately 138 centimeters in length.
  • the NVS therapeutic catheter is compatible with a 7F Cook Ansel Introducer Sheath.
  • the main catheter shaft is composed of a polymeric composition which provides suitable column strength and flexibility to controllably advance through tortuous vasculature to the target vascular treatment site.
  • An exemplary polymeric composition for the catheter shaft is a PebaxTM 7233 polyetheramide block copolymer, formed by a single extrusion, with a radially- symmetrical, five-lumen construction, and having a light transmission efficiency of better than 90% from the central-most lumen through the outer wall.
  • a cross-sectional view of an exemplary, co-extruded catheter shaft having five lumens is depicted in FIG. 2.
  • Proximally disposed Luer hubs 120 communicate with each lumen 111, 112, 113, 114, and 115 of the main shaft through dedicated extension tubing 121, 122, 123, 124, and 125 comprising suitable polymeric materials, such as elastomeric PVC or nylon single lumen tubing.
  • the extension tubing may be thermally bonded or adhesively bonded to a proximal manifold which unitizes the catheter components to effect independent fluid or component access to the three distal, inflatable balloons 132, 134, and 136, as well as the guide wire lumen 111, and the injection port to the NVS composition infusion lumen 114.
  • a first catheter lumen 111 is provided along the full length of the NVS catheter sufficient in size to slidably accommodate a guidewire having a diameter of 0.018 inches, over which the catheter is delivered, following removal of the pre- dilatation PTA catheter.
  • the catheter incorporates dual occlusion balloons, comprising proximal occlusion balloon (PROX OB in FIG. 1) 132 and distal occlusion balloon (DIST OB in FIG. 1) 134, which are formed of a relatively high compliance polymeric material, such as PellethaneTM 80 AE elastomeric polyurethane polymer.
  • these occlusion balloons 132 and 134 are sized to occlude vessel lumens from approximately 4 to 9 mm diameter over a length of up to 10mm.
  • the proximal occlusion balloon 132 and the distal occlusion balloon 134 are provided inflation fluid by an independent second catheter lumen 112 and a third catheter lumen 113, which respectively extend from the proximal end 102 of the catheter to their respective occlusion balloons 132 and 134.
  • the occlusion balloons cooperatively function to temporarily isolate the treated region of the vessel from blood flow.
  • An infusion outlet port (Injection site in FIG. 1) 140 is provided at the distal end 142 of the fourth lumen 114, and is located approximately 3 mm distal from the proximal occlusion balloon 132 but proximal of the distal occlusion balloon 134. This infusion outlet port is used to infuse the NVS composition into the treated region of the vessel.
  • the Natural Vascular Scaffolding (NVS) composition is referred to as 10-8-10PAS or BL-8.
  • the chemical composition of the Natural Vascular Scaffolding (NVS) solution is 2-[2-[2-(2- aminoethoxy)ethoxy]ethyl]-6-[2-[2-[[2-[2-[2-(2- aminoethoxy)ethoxy]ethyl]-l,3-dioxo-benzo[de]isoquinolin-6- yl]amino]ethoxy]ethoxy]ethylamino]benzo[de]isoquinoline-l,3-dione, (C 4 2H52N6Oio),MW 800 g/mol, suspended at a concentration of 2.0 mg/ml in phosphate buffered saline (PBS) at pH 7.4.
  • PBS phosphate buffered saline
  • NVS solution is an orange-colored solution with a viscosity very close to that of water.
  • the NVS solution contains 2.0 mg/mL of the NVS composition, and it is administered at a dose of 250 of NVS Solution per cm of treatment region relative to superior femoral arteries (SFA) having vessel diameters ranging from 4.0 - 8.0 mm..
  • SFA superior femoral arteries
  • a primary dilatation balloon (TZB or Treatment Zone Balloon in FIG. 1) 136 is located at the distal end 104 of the catheter shaft, and is positioned between the dual occlusion balloons 132 and 134.
  • the primary dilatation balloon is comprised of a relatively semi-compliant polymeric balloon material, such as VestamidTM L2101F nylon-12 polymer, with a nominal compliance of approximately ten percent (10%) over a pressure range of 7 to 12 atmospheres.
  • the primary dilatation balloon 136 is provided inflation fluid by a fifth lumen (TZB lumen in FIG. 1) 115 extending nearly the full length of the catheter.
  • radiopaque marker bands 350 and 352 are located at each shoulder of the primary dilatation balloon 136 to delineate the working length of the working section of the balloon and aid in its proper placement relative to the vascular treatment site. Additionally, radiopaque marker bands 354 and 356 are each located in the center of each respective occlusion balloon to further assist in catheter placement.
  • an interventional NVS procedure involving the SFA would preferably provide NVS therapeutic catheters having different lengths, perhaps ranging from 80 to 100 mm, and with various diameters ranging from 4 to 7 mm.
  • Use of the NVS therapeutic catheter 100 is as follows.
  • the proximal occlusion balloon 132 is first inflated, followed by injection of a saline flush through the fourth lumen 114 to temporarily purge blood from the region of the vessel to be treated. Thereafter, the distal occlusion balloon 134 is inflated, to effectively isolate the treated region of the vessel from blood flow. While the dual occlusion balloons 132 and 134 are temporarily inflated, the NVS composition is infused into the isolated region of the vessel to be treated, and the temporary interruption of blood flow in the treated region of the vessel permits sufficient time for the NVS composition to diffuse fully into the vascular tissues (e.g., intima, media and adventitia). The time required for adequate tissue perfusion of the vessel wall will vary depending upon the size of the vessel being treated, as well as the particular NVS composition being used, but perfusion / soak times ranging between 3 to 6 minutes should be sufficient for most circumstances.
  • vascular tissues e.g., intima, media and adventitia
  • the primary dilatation balloon which is located between the dual occlusion balloons, is inflated to reestablish the desired lumen diameter and cylindrical shape at the region of the vessel being treated.
  • the reestablished lumen vessel diameter should be at least as great as the diameter of normal vasculature in the immediate vicinity.
  • this method may further comprise after the step of isolating, a step of expanding a vessel lumen having a first diameter, which is smaller than a normal lumen diameter for the vessel at a location adjacent to the isolated section, to a second diameter which is equal to or greater than the normal lumen diameter.
  • the second lumen diameter can be maintained during an activating step.
  • the second diameter of the lumen can comprise a diameter which exceeds the normal diameter by up to thirty percent.
  • the lumen diameter can be expanded by balloon angioplasty.
  • the step of expanding can be performed at least one of prior to, during, and subsequent to the applying step.
  • the method may further comprise a step of activating the NVS composition with a sufficient amount of an activating agent, such as photoactivation.
  • the NVS catheter can be used for both the primary PTA dilation procedure, by inflating the primary dilation balloon to restore the desired lumen diameter, followed by deflating the primary dilation balloon and proceeding to occlude, infuse, and photoactivate the vessel, as previously described, to perform the NVS therapy.
  • severely narrowed vessels may require that the initial PTA procedure be performed by an separate and independent PTA catheter having a sufficiently low profile to cross the lesion.
  • An exemplary light fiber 480 is depicted in FIG. 4.
  • An exemplary light fiber comprises a plastic optical fiber (POF) comprising a core of materials such as nylon, polymethylmethacrylate (PMMA, or acrylic polymer) and having a nominal diameter of approximately 0.20 inches, coated with a fluoropolymer cladding material of nominal 10 micron wall thickness.
  • PPF plastic optical fiber
  • the POF is of sufficient length that it may be proximally attached, via an SMA 905 connector, to a laser powered light source of approximately 430 to 470 nm wavelength, which is deemed to sufficiently photoactivate the NVS compositions previously disclosed.
  • the light fiber 480 is designed to extend distally to allow light emanation within the primary dilatation balloon 136 of the catheter 100 described above. It is contemplated that the light fiber 480 can alternatively be permanently integrated into the catheter shaft. Additionally, it is also contemplated that it is possible to substitute the fiber and light diffuser with an LED array disposed at the distal end of the NVS delivery catheter.
  • the light required for the photo-activation of the NVS solution is delivered by the light fiber 480, which in one embodiment was machined from a Mitsubishi SK-20 Medical Grade light fiber (Mitsubishi Rayon Co., Ltd., Tokyo, Japan), comprised of a polymethyl methacrylate core with a fluorinated polymer cladding material, and having a diameter of 0.020 inches.
  • the proximal end of the fiber 480 is provided with a Sub-Miniature Version A (SMA) optical connector to enable connection to an external light source.
  • SMA Sub-Miniature Version A
  • the distal end of the fiber 480 is laser etched to provide a radial light emission pattern comparable in size to full length of the PTA dilatation balloon.
  • the light fiber 480 utilizes a helical laser etching pattern
  • an excimer laser is utilized to etch the desired patterns on short (1cm) fibers.
  • the excimer laser ablates the outer sheath and provides aggressive light harvesting potential.
  • a femtosecond laser is utilized to etch the desired pattern on longer light fibers, producing a more subtle disruption between the core and the cladding. This subtle disruption is more useful in the production of longer light fibers.
  • the etching pattern of the cut is designed to more aggressively harvest the light near the distal end of the fiber where the flux of light through the core has been diminished.
  • the exemplary light fiber 480 of the present disclosure incorporates a light diffuser 490 disposed at the distal end 482 of the fiber, formed by creating an array of closely-spaced, helically- arranged, circular etchings or pits 492 through the outer cladding of the fiber optic.
  • These helical etchings 492 are produced by use of a programmable work station in combination with a femtosecond laser (e.g., a laser power of 10 uJ / pulse, operating at a pulse rate of 51.86 Hz pulse rate, producing a wavelength of approximately 1,150 nm), which manipulates the rotation and longitudinal rotation of the fiber relative to the laser beam, as well as modulating the laser pulses applied to the fiber, to provide helical etchings having a pattern with a variable pitch 494 which results in higher density etchings progressing from the proximal to the distal end of the diffuser.
  • a femtosecond laser e.g., a laser power of 10 uJ / pulse, operating at a pulse rate of 51.86 Hz pulse rate, producing a wavelength of approximately 1,150 nm
  • variable helical etching pattern is provided to accommodate the attenuation of light energy over the length of the diffuser, thereby generating a more uniform flux density of light emission along the region of the vessel being treated, and thus a more uniform degree of photoactivation and cross-linking within the collagen of the vessel.
  • the objective using this etching technique would be to produce optical diffusers which can operate at a relatively high radial emission efficiency, such as ninety percent (90%).
  • alternative laser technology such as eximer lasers, would not be as effective for this optical fiber etching process, since eximer lasers are more prone to drift, are less precise and produce a wider cutting kerf than the femtosecond lasers.
  • these pitted laser etchings provide discontinuities at the cladding core interface which produce back- scatter of beams propagating longitudinally through the optic fiber core.
  • any back-scatter rays which are produced at the respective etched pit will produce some rays which continue to reflect within the core along its length occasionally reflecting between opposing cladding surfaces.
  • that back-scatter rays which are produced at the respective etched pit exceed a critical angle relative to the interface between the outer surface of the core and cladding, then that portion of back-scatter rays will escape from the fiber optic core emerging out from the opposite side of the pitted etching which initially produced the back- scatter.
  • the effective radial emissions along the length of the diffuser are kept relative uniform, preferably within a tolerance of no more than about ⁇ 10%.
  • the light fiber 480 is sized to extend the length of the catheter shaft, and the light diffuser 490 which is located at the distal end 482 of the light fiber. More particularly, the light diffuser 490 is spaced an appropriate distance from the proximal end 484 of the light fiber, such that upon insertion into the first catheter lumen 111, the light diffuser 490 will be coextensively disposed to align with the region of the vessel to be treated.
  • the relative length of the light diffuser 490 is preferably selected to be of a length approximating the length of lesions to be treated in stenosed vasculature, such as diffuser lengths varying from 40 to 100 mm, but greater lengths may be needed for treatment of diffuse lesions in various anatomy, such as the superficial femoral artery (SFA).
  • SFA superficial femoral artery
  • NVS superficial femoral artery
  • a reusable, external light source comprising a blue diode emitter which is capable of producing approximately 3 Watts of power, with alternatively power ranges from 2.0 - 5.0 Watts, is coupled to the proximal end of the NVS catheter 100 to deliver light to the distal end of the catheter via the light fiber 480.
  • the light source generates an output of light at approximately 450 nm (i.e., nominally between 420 - 490 nm), which is laterally scattered by the light diffuser 490 and passes through the translucent primary inflation balloon 136, and ultimately diffuses into the adjacent tissue of the vessel wall, with a sufficient quantum of light energy (e.g., radial emissions having a flux density of 100 mWatts / cm for an artery having a dimension of 8 cm length x 7 mm diameter) to photoactivate the NVS composition, which cleaves the NVS molecule, and releases the PEG linkers which are photochemically produced as a reactive intermediate and will bind to collagen within the vascular tissue.
  • a sufficient quantum of light energy e.g., radial emissions having a flux density of 100 mWatts / cm for an artery having a dimension of 8 cm length x 7 mm diameter
  • the photoactivation period will vary depending upon the size of the vessel being treated, as well as the particular NVS composition being used, but activation times ranging from 30 to 90 seconds should be sufficient for most circumstances, and more preferably at about 60 seconds. Thereafter, the light source is turned off.
  • the PEG linkers which have now disassociated from the naphthalimide molecules, present active sites at each end which readily cross-link with native collagen fibrils that are naturally prevalent within all tissue layers of the arterial wall. Because the primary inflation balloon 136 has dilated the vessel lumen to its desired diameter prior to photoactivation of the NVS composition, the cross-linking process fixates the proteins within the vessel wall, including the collagen fibrils which are now oriented in the desired geometric profile following dilatation. Thus, the cross-linking process will cause the post-angioplasty configuration of the vessel lumen to fixate at the desired orientation, and the reestablished vessel lumen will be maintained, even after removal of the NVS therapeutic catheter. Thus, the present disclosure is believed to prevent acute vessel recoil, as well as reduced trauma and potential for excessive post-dilation inflammatory response and restenosis.
  • the NVS delivery catheter and guidewire are removed, leaving a reinforced collagen scaffolding at the treated region of the vessel, thereby serving as an endogenous stent which presents no prosthetic structure that extends inwardly into the vessel lumen. Consequently, future interventions to treat the vessel can be practiced without concern of having to re-cross implantable prosthetic stents. Moreover, it is believed that the risk of thrombosis and in-stent restenosis are concomitantly reduced.
  • NVS compositions designed to releasably tether therapeutic drugs to perform adjunctive, intramural drug delivery is practiced by similar clinical fashion.
  • the desired therapeutic agent has been releaseably coupled to the NVS composition by means of a specially-designed tether linkage.
  • the tether linkage for drug delivery can comprise a PEG linker, or any other linker suitable for tethering the drug to the naphthalimide.
  • the tether linkage disassociates at one end from the respective naphthalimide molecule, and carries the tethered drug along with it to bind with native proteins (i.e., collagen) within the vascular tissues.
  • native proteins i.e., collagen
  • the protocol used in various vascular studies involved the following parameters, namely: 1) NVS solution concentration of 2.0 mg/mL;
  • NVS solution photo-activation power 225 mW/cm of vascular treatment region, which equates to power delivery of approximately
  • FIG. 5 a longitudinal cross-sectional view illustrates the distal region 200 of a balloon catheter assembly 500.
  • a catheter shaft 30 encloses the first tubular member 202, the second tubular member 212 and the third tubular member 222 in a side-by-side configuration.
  • the third tubular member 222 defines a guidewire lumen 226 configured to receive a guidewire.
  • the proximal seal 242a joins an outer balloon 42 to the catheter shaft 30 proximal to the distal end 212b of the second tubular member 212 and the proximal seal 244a of the inner balloon 44.
  • the outer balloon 42 is disposed circumferentially around the inner balloon 44, defining the balloon fluid delivery lumen 242 extends longitudinally from the proximal seal 242a to the distal seal 242b around the third tubular member 222.
  • the outer balloon 42 includes a microporous portion 243 include a plurality of micropores 43, which are sized and distributed across the central portion of outer balloon 42 such that continued injection of NVS composition into the outer balloon will provide a uniform, gentle, weeping outflow into the lesion and associated vascular tissue. It should be appreciated that the NVS composition is designed to soften calcified plaque.
  • An inner balloon 44 proximal seal 244a joins the inner balloon 44 around both the first tubular member 202 and the third tubular member 222, proximal to the distal end 202b of the first tubular member 202.
  • the inner balloon 44 is disposed circumferentially around the third tubular member 222 and defines the balloon inflation lumen 244 extending longitudinally from the proximal seal 244a to the distal seal 244b around the third tubular member 222.
  • the distal seal 242b may overlap or be positioned around the distal seal 244b.
  • the distal seal 244b of the inner balloon 44 is positioned proximal to the distal seal 242b of the outer balloon 42.
  • thermoformable material may be placed between the distal end 202b of the first tubular member 202 and the third tubular member 222. It some embodiments, it may be preferred that the distalmost portion of the third tubular member 222, which traverses the length of the inner and outer balloons 44, 42, is formed of a translucent polymeric material.
  • the inner balloon 44 and the outer balloon 42 may be formed from a semi-compliant expandable material.
  • the inner balloon 44 and the outer balloon 42 are formed from the materials having a similar Young's modulus and expandability.
  • the balloons may be formed from a polyamide (e.g., nylon 12) material, a polyamide block copolymer (e.g., PEBA) and blends thereof (e.g., nylon 12/PEBA and PEBA/PEBA blends).
  • Alternative materials include polyolefins, polyolefin copolymers and blends thereof; polyesters (e.g., poly(ethylene terephthalate), PET); polyure thane copolymers with MDI, HMDI or TDI hard segment and aliphatic polyester, polyether or polycarbonate soft segment (e.g., Pellethane, Estane or Bionate); and polyester copolymers with 4GT (PBT) hard segment and aliphatic polyester or polyether soft segments (e.g., Hytrel, Pelprene or Arnitel). It some embodiments, it may be preferred to form both the inner and outer balloons from the save polymeric material, such as for example, Nylon 12.
  • polyesters e.g., poly(ethylene terephthalate), PET
  • 242b, 244a, 244b) may be formed in any suitable manner.
  • the proximal and distal inner surfaces of the balloons 42, 44 are sealably attached to the catheter shaft 30 or a tubular member, as described above.
  • Means of sealing the balloons 42, 44 include, for example, heat sealing, using an adhesive to form the seal, forced convection heating, radio frequency heating, ultrasonic welding, and laser bonding.
  • Shrink tubing may be used as a manufacturing aid to compress and fuse the balloon 42, 44 to the catheter shaft 30 or a tubular member 202, 212, 222. The shrink tubing may be removed and disposed of after the balloon 42, 44 is sealed, or may remain on as part of the connected structure. If the catheter shaft 30 has an outer coating, the balloon 42, 44 may be bonded to the coating or directly to the catheter shaft 30.
  • the inflated diameter of the outer balloon 42 may be about 1.5 mm (0.059-inches) to about 8 mm (0.3-inches), while a catheter intended for coronary vascular applications preferably has an expandable portion 14 with an inflated diameter range of from about 1.5 mm (0.059-inches) to about 4 mm (0.2 inches).
  • the expanded diameter of the outer balloon 42 may be about 5-15 mm (0.2-0.59-inches) with a length of approximately 15- 60 mm (0.59-2.4 inches), and the outer diameter of the catheter shaft 30 may be up to about 3.5 mm (0.14-inches).
  • the catheter shaft may be about 3-12 French between proximal to the balloons (i.e., an outer diameter of about 1 mm-4 mm (0.04-0.16-inches)), and preferably about 4-8 French.
  • the exemplary embodiment of FIG. 5 is suitable for a use similar to that described above relative to the embodiments of FIGS. 1-4. However, the protocol by which the device of FIG. 5 is utilized differs from that of the device of FIGS. 1-4, as described in more detail below. For example, once the distal region 200 of the balloon catheter assembly 500 is properly positioned such that the dual concentric balloons 42, 44 are disposed directly beneath the vascular lesion to be treated, the preferred protocol using the device of FIG.
  • NVS composition will deliver NVS composition to the lesion and vascular tissue prior to the final dilation using the inner balloon 44.
  • a clinical advantage may be attained using the device of FIG. 5 according to this revised protocol because any calcified plaque present within the lesion being treated can be softened prior to dilating the inner balloon 44. Consequently, this improved protocol will reduce the incidence of vascular trauma and potential microdissection of vascular tissue. Accordingly, the NVS composition is delivered through tubular member 212 and into the annular space 242 defined between the outer surface of the inner balloon 44 and the inner surface of the outer balloon 42.
  • the remaining steps of the protocol include inflating the inner balloon to achieve the desired luminal gain at the lesion site, followed by an exchange of the guidewire with a fiberoptic provided with a light diffuser, such as that shown and described with respect to FIG. 4. Once the diffuser is properly positioned beneath the two balloons 42, 44, light energy is applied to the proximal end of the catheter, as discussed relative to the embodiments above, to photoactivate the NVS composition and reinforce native collagen. After photoactivation, the catheter assembly 500 is removed from the patient.
  • the balloon catheter assembly 10 may include radiopaque material to provide a means for locating the balloon catheter assembly 10 within a body vessel.
  • the third tubular member 222 may include one or more marker bands 252 annularly disposed around the outside of the third tubular member 222 within the inner balloon 44.
  • radiopaque bands 252 may be added to the third tubular member 222.
  • Radiopaque marker bands 252 may be used by a clinician to fluoroscopically view and locate the distal portion 200 of the balloon catheter assembly 10 at a treatment site within a body vessel.
  • Various configurations of radiopaque marker bands 252 may be used.
  • radiopaque marker band 252 may be located on a distal end 4 and/or on the third tubular member 222 within the inner balloon 44. As shown, the radiopaque marker bands 252 may be stripes.
  • radiopaque markers may be constructed by encapsulating a radiopaque material, such as a metallic ring, within the material of catheter shaft.
  • a portion of the catheter shaft may be made radiopaque for example by constructing the portion from a radiopaque polymer.
  • a polymer may be mixed with a radiopaque filler such as barium sulfate, bismuth trioxide, bismuth subcarbonate or tungsten.
  • the radiopaque material can comprise any suitable opacifying agent, further including bismuth, tantalum, or other suitable agents known in the art.
  • the concentration of the agent in the coating may be selected to be adequately visible under fluoroscopy.
  • the NVS solution can be delivered to the stenosed artery using a TAP AS ® delivery catheter (distributed by Spectranetics Corporation, Colorado Springs, Colorado).
  • the TAP AS ® catheter is indicated for general intravascular use in the peripheral vasculature in arteries with a luminal diameter of 1.8 mm and larger.
  • the delivery catheter comprises a catheter shaft having two longitudinally-spaced apart occlusion balloons at the distal end of the catheter.
  • the delivery catheter also includes an infusion lumen having an infusion delivery port disposed between the occlusion balloons to facilitate infusion of diagnostic or therapeutic agents into the vascular region to be treated while the occlusion balloons are inflated to isolate the treatment site from blood flow.
  • the TAP AS ® delivery catheter is infuses the NVS solution to the isolated vascular treatment region, which is allowed to passively soak into the tissue of the vascular wall for a predetermined period of time (e.g., 5 minutes). Thereafter, the delivery catheter is removed from the artery and replaced with a marketed PTA balloon dilatation catheter indicated for use in the peripheral vasculature. Once the PTA dilatation catheter is positioned over the introduction guidewire at the vascular treatment site, the guidewire is removed and replaced with the NVS light fiber having a distal diffuser which is suitable to provide the light energy necessary for the photo-activation of the NVS solution which has permeated the vascular tissue.
  • the PTA balloon is then inflated to restore the stenosed vascular region to the desired luminal diameter.
  • the PTA dilatation is maintained in the inflated state while photo-activation is provided to the treatment site through the light fiber (e.g., photo-activation using 457 nm light at approximately 225mW / cm of treatment region for approximately 60 seconds) to facilitate crosslinking within the artery tissue.
  • the light fiber e.g., photo-activation using 457 nm light at approximately 225mW / cm of treatment region for approximately 60 seconds
  • the PTA balloon is deflated, and the light fiber is removed and replaced with the guidewire, upon which the PTA catheter is removed, and the treatment is complete.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

La présente invention concerne un dispositif thérapeutique vasculaire d'intervention (100) comprenant une tige de cathéter (110) comportant une paire de ballons d'occlusion (132, 134), un ballon de dilatation (136) disposé sur la tige de cathéter entre les ballons d'occlusion, une première lumière de gonflage (112) et une deuxième lumière de gonflage (113) conçues pour alimenter en fluide de gonflage un ballon disposé de manière proximale et un ballon distal parmi les ballons d'occlusion, une troisième lumière de gonflage (115) conçue pour alimenter en fluide de gonflage le ballon de dilatation, une lumière principale (111) s'étendant sur toute la longueur du cathéter et conçue pour recevoir de manière coulissante un fil de guidage, et une lumière de perfusion (114) s'étendant à partir d'une extrémité proximale de la tige de cathéter en direction de l'extrémité distale de la tige de cathéter et se terminant au niveau d'un orifice de sortie (140) de perfusion situé entre les ballons d'occlusion. Le dispositif selon l'invention comprend une fibre optique (480) conçue pour être insérée dans la lumière principale à la place du fil de guidage.
PCT/US2013/053671 2012-08-03 2013-08-05 Cathéters à ballons multiples endovasculaires à diffuseur optique pour le traitement de sténoses vasculaires WO2014022867A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261679591P 2012-08-03 2012-08-03
US61/679,591 2012-08-03
US201361794725P 2013-03-15 2013-03-15
US61/794,725 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014022867A1 true WO2014022867A1 (fr) 2014-02-06
WO2014022867A8 WO2014022867A8 (fr) 2014-12-31

Family

ID=49029196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/053671 WO2014022867A1 (fr) 2012-08-03 2013-08-05 Cathéters à ballons multiples endovasculaires à diffuseur optique pour le traitement de sténoses vasculaires

Country Status (1)

Country Link
WO (1) WO2014022867A1 (fr)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104434258A (zh) * 2014-11-28 2015-03-25 苏州亘科医疗科技有限公司 一种多功能球囊扩张导管
WO2016147191A1 (fr) * 2015-03-18 2016-09-22 Mor Research Applications Ltd. Modification percutanée de la matrice extracellulaire vasculaire pour prévenir et traiter la resténose vasculaire
CN107343980A (zh) * 2016-04-21 2017-11-14 青岛智辰生物科技有限公司 一种多腔道球囊导管
WO2018056940A3 (fr) * 2016-07-13 2018-07-12 Erkin Alper Nouveau système d'ablation mécanochimique par voie intraveineuse à utiliser pour le traitement de veines variqueuses
CN109224264A (zh) * 2018-07-30 2019-01-18 郑州大学第附属医院 用于心血管介入治疗的锥形扩张球囊
WO2019034778A1 (fr) * 2017-08-17 2019-02-21 Koninklijke Philips N.V. Dispositifs d'occlusion temporaire à ballonnet, systèmes et procédés de prévention d'écoulement à travers une perforation vasculaire
WO2020024612A1 (fr) * 2018-08-03 2020-02-06 东莞天天向上医疗科技有限公司 Cathéter à ballonnet ayant de multiples canaux et de multiples ballonnets pour arrêter rapidement un saignement dans des vaisseaux sanguins
WO2020069188A1 (fr) * 2018-09-26 2020-04-02 W. L. Gore & Associates, Inc. Programmes de traitement de tissu à dilatation cyclique, et systèmes associés
WO2020072467A1 (fr) 2018-10-02 2020-04-09 Alucent Biomedical, Inc. Appareil et méthodes pour échafaudage
CN111248964A (zh) * 2020-01-16 2020-06-09 张跃国 一种心血管内科介入装置
WO2020180638A1 (fr) 2019-03-01 2020-09-10 Alucent Biomedical, Inc. Appareil et procédés pour restaurer un tissu
WO2020256898A1 (fr) * 2019-06-19 2020-12-24 Boston Scientific Scimed, Inc. Génération d'ondes de pression photoacoustiques depuis une surface de ballonnet pour réduire des lésions vasculaires
WO2021022159A1 (fr) * 2019-07-31 2021-02-04 Alucent Biomedical, Inc. Appareil et méthodes pour restaurer un tissu
WO2021101858A1 (fr) * 2019-11-18 2021-05-27 Alucent Biomedical, Inc. Appareil et méthodes de restauration de tissus
WO2022036263A1 (fr) * 2020-08-13 2022-02-17 Cedars-Sinai Medical Center Thérapie par ultraviolets interne
CN114082086A (zh) * 2021-12-23 2022-02-25 赛诺神畅医疗科技有限公司 一种球囊导引导管
WO2022164879A1 (fr) * 2021-01-27 2022-08-04 Wake Forest University Health Sciences Cathéters à ballonnet à lumières multiples appropriés pour une cholangiographie d'occlusion par ballonnet et une dilatation de sphincter d'oddi et procédés d'utilisation associés
CN114931695A (zh) * 2022-05-11 2022-08-23 上海玮沐医疗科技有限公司 一种带有光固化涂层的冲击波球囊导管装置
US20220273915A1 (en) * 2021-02-26 2022-09-01 Alucent Biomedical, Inc. Apparatus and methods for restoring tissue
WO2022237114A1 (fr) * 2021-05-13 2022-11-17 王雅 Cathéter à ballonnet ayant un trou latéral dans un corps principal de cathéter derrière un ballonnet
US11517713B2 (en) 2019-06-26 2022-12-06 Boston Scientific Scimed, Inc. Light guide protection structures for plasma system to disrupt vascular lesions
US11583339B2 (en) 2019-10-31 2023-02-21 Bolt Medical, Inc. Asymmetrical balloon for intravascular lithotripsy device and method
EP4162967A1 (fr) * 2021-10-08 2023-04-12 WeMed Technologies GmbH Système de cathéter à ballonnet
US11648057B2 (en) 2021-05-10 2023-05-16 Bolt Medical, Inc. Optical analyzer assembly with safety shutdown system for intravascular lithotripsy device
US11660427B2 (en) 2019-06-24 2023-05-30 Boston Scientific Scimed, Inc. Superheating system for inertial impulse generation to disrupt vascular lesions
US11672585B2 (en) 2021-01-12 2023-06-13 Bolt Medical, Inc. Balloon assembly for valvuloplasty catheter system
US11672599B2 (en) 2020-03-09 2023-06-13 Bolt Medical, Inc. Acoustic performance monitoring system and method within intravascular lithotripsy device
US11707323B2 (en) 2020-04-03 2023-07-25 Bolt Medical, Inc. Electrical analyzer assembly for intravascular lithotripsy device
US11717139B2 (en) 2019-06-19 2023-08-08 Bolt Medical, Inc. Plasma creation via nonaqueous optical breakdown of laser pulse energy for breakup of vascular calcium
US11806075B2 (en) 2021-06-07 2023-11-07 Bolt Medical, Inc. Active alignment system and method for laser optical coupling
US11839391B2 (en) 2021-12-14 2023-12-12 Bolt Medical, Inc. Optical emitter housing assembly for intravascular lithotripsy device
WO2024030552A1 (fr) * 2022-08-03 2024-02-08 Zeus Company Inc. Fibre optique polymère
US11903642B2 (en) 2020-03-18 2024-02-20 Bolt Medical, Inc. Optical analyzer assembly and method for intravascular lithotripsy device
WO2024045982A1 (fr) * 2022-09-02 2024-03-07 杭州矩正医疗科技有限公司 Cathéter à ballonnet de support de médicament et sa méthode de préparation, système de cathéter à ballonnet et méthode de génération de stent intravasculaire in situ
WO2024049814A1 (fr) * 2022-08-31 2024-03-07 Medtronic, Inc. Cathéter à ballonnet multimodal comprenant un ballonnet pour lithotritie
US11992699B2 (en) 2019-10-15 2024-05-28 Cedars-Sinai Medical Center Internal ultraviolet therapy
CN118161730A (zh) * 2024-05-13 2024-06-11 鼎科医疗技术（苏州）有限公司 一种药物球囊导管及其涂层制备方法
US12016610B2 (en) 2020-12-11 2024-06-25 Bolt Medical, Inc. Catheter system for valvuloplasty procedure
WO2024150193A1 (fr) * 2023-01-13 2024-07-18 Incite Medical Sarl Cathéter à ballonnet pour perfusion sélective de vaisseau latéral
WO2024158889A1 (fr) * 2023-01-27 2024-08-02 Mavericks Foundation Llc Systèmes et procédés pour retrait de ballonnet de cathéter
US12102384B2 (en) 2019-11-13 2024-10-01 Bolt Medical, Inc. Dynamic intravascular lithotripsy device with movable energy guide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5779673A (en) * 1995-06-26 1998-07-14 Focal, Inc. Devices and methods for application of intraluminal photopolymerized gels
US20040024419A1 (en) * 1988-08-24 2004-02-05 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use therein
US20040059290A1 (en) * 2002-09-24 2004-03-25 Maria Palasis Multi-balloon catheter with hydrogel coating
US20070237739A1 (en) * 2006-04-07 2007-10-11 Medtronic Vascular, Inc., A Delaware Corporation Closed Loop Catheter Photopolymerization System and Method of Treating a Vascular Condition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024419A1 (en) * 1988-08-24 2004-02-05 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use therein
US5779673A (en) * 1995-06-26 1998-07-14 Focal, Inc. Devices and methods for application of intraluminal photopolymerized gels
US20040059290A1 (en) * 2002-09-24 2004-03-25 Maria Palasis Multi-balloon catheter with hydrogel coating
US20070237739A1 (en) * 2006-04-07 2007-10-11 Medtronic Vascular, Inc., A Delaware Corporation Closed Loop Catheter Photopolymerization System and Method of Treating a Vascular Condition

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104434258A (zh) * 2014-11-28 2015-03-25 苏州亘科医疗科技有限公司 一种多功能球囊扩张导管
WO2016147191A1 (fr) * 2015-03-18 2016-09-22 Mor Research Applications Ltd. Modification percutanée de la matrice extracellulaire vasculaire pour prévenir et traiter la resténose vasculaire
US20180056086A1 (en) * 2015-03-18 2018-03-01 Mor Research Applications Ltd. Percutaneous modification of vascular extracellular matrix to prevent and treat vascular restenosis
CN107343980A (zh) * 2016-04-21 2017-11-14 青岛智辰生物科技有限公司 一种多腔道球囊导管
WO2018056940A3 (fr) * 2016-07-13 2018-07-12 Erkin Alper Nouveau système d'ablation mécanochimique par voie intraveineuse à utiliser pour le traitement de veines variqueuses
CN111225622A (zh) * 2017-08-17 2020-06-02 皇家飞利浦有限公司 用于防止流过血管穿孔的临时性闭塞球囊装置、系统和方法
WO2019034778A1 (fr) * 2017-08-17 2019-02-21 Koninklijke Philips N.V. Dispositifs d'occlusion temporaire à ballonnet, systèmes et procédés de prévention d'écoulement à travers une perforation vasculaire
CN111225622B (zh) * 2017-08-17 2023-11-07 皇家飞利浦有限公司 用于防止流过血管穿孔的临时性闭塞球囊装置、系统和方法
CN109224264A (zh) * 2018-07-30 2019-01-18 郑州大学第附属医院 用于心血管介入治疗的锥形扩张球囊
WO2020024612A1 (fr) * 2018-08-03 2020-02-06 东莞天天向上医疗科技有限公司 Cathéter à ballonnet ayant de multiples canaux et de multiples ballonnets pour arrêter rapidement un saignement dans des vaisseaux sanguins
WO2020069188A1 (fr) * 2018-09-26 2020-04-02 W. L. Gore & Associates, Inc. Programmes de traitement de tissu à dilatation cyclique, et systèmes associés
AU2019346610B2 (en) * 2018-09-26 2022-07-14 W. L. Gore & Associates, Inc. Cyclic expansion tissue treatment programs and associated systems
US11541204B2 (en) 2018-09-26 2023-01-03 W. L. Gore & Associates, Inc. Cyclic expansion tissue treatment programs and associated systems
CN112770684A (zh) * 2018-09-26 2021-05-07 W.L.戈尔及同仁股份有限公司 循环扩张组织治疗程序及相关联的系统
US11090467B2 (en) 2018-10-02 2021-08-17 Alucent Biomedical, Inc. Apparatus and methods for scaffolding
EP3860529A4 (fr) * 2018-10-02 2022-11-02 Alucent Biomedical, Inc. Appareil et méthodes pour échafaudage
WO2020072467A1 (fr) 2018-10-02 2020-04-09 Alucent Biomedical, Inc. Appareil et méthodes pour échafaudage
WO2020180638A1 (fr) 2019-03-01 2020-09-10 Alucent Biomedical, Inc. Appareil et procédés pour restaurer un tissu
EP3930820A4 (fr) * 2019-03-01 2022-12-14 Alucent Biomedical, Inc. Appareil et procédés pour restaurer un tissu
US11717139B2 (en) 2019-06-19 2023-08-08 Bolt Medical, Inc. Plasma creation via nonaqueous optical breakdown of laser pulse energy for breakup of vascular calcium
WO2020256898A1 (fr) * 2019-06-19 2020-12-24 Boston Scientific Scimed, Inc. Génération d'ondes de pression photoacoustiques depuis une surface de ballonnet pour réduire des lésions vasculaires
US11819229B2 (en) 2019-06-19 2023-11-21 Boston Scientific Scimed, Inc. Balloon surface photoacoustic pressure wave generation to disrupt vascular lesions
US11660427B2 (en) 2019-06-24 2023-05-30 Boston Scientific Scimed, Inc. Superheating system for inertial impulse generation to disrupt vascular lesions
US11517713B2 (en) 2019-06-26 2022-12-06 Boston Scientific Scimed, Inc. Light guide protection structures for plasma system to disrupt vascular lesions
US11911574B2 (en) 2019-06-26 2024-02-27 Boston Scientific Scimed, Inc. Fortified balloon inflation fluid for plasma system to disrupt vascular lesions
WO2021022159A1 (fr) * 2019-07-31 2021-02-04 Alucent Biomedical, Inc. Appareil et méthodes pour restaurer un tissu
CN114514046B (zh) * 2019-07-31 2024-03-08 奥卢森特生物医学公司 用于修复组织的装置和方法
EP4003484A4 (fr) * 2019-07-31 2023-09-06 Alucent Biomedical, Inc. Appareil et méthodes pour restaurer un tissu
CN114514046A (zh) * 2019-07-31 2022-05-17 奥卢森特生物医学公司 用于修复组织的装置和方法
US11992699B2 (en) 2019-10-15 2024-05-28 Cedars-Sinai Medical Center Internal ultraviolet therapy
US11583339B2 (en) 2019-10-31 2023-02-21 Bolt Medical, Inc. Asymmetrical balloon for intravascular lithotripsy device and method
US12102384B2 (en) 2019-11-13 2024-10-01 Bolt Medical, Inc. Dynamic intravascular lithotripsy device with movable energy guide
CN114616018A (zh) * 2019-11-18 2022-06-10 奥卢森特生物医学公司 用于修复组织的装置和方法
WO2021101858A1 (fr) * 2019-11-18 2021-05-27 Alucent Biomedical, Inc. Appareil et méthodes de restauration de tissus
US11529499B2 (en) * 2019-11-18 2022-12-20 Alucent Biomedical, Inc. Apparatus and methods for restoring tissue
CN111248964B (zh) * 2020-01-16 2020-11-13 张跃国 一种心血管内科介入装置
CN111248964A (zh) * 2020-01-16 2020-06-09 张跃国 一种心血管内科介入装置
US11672599B2 (en) 2020-03-09 2023-06-13 Bolt Medical, Inc. Acoustic performance monitoring system and method within intravascular lithotripsy device
US11903642B2 (en) 2020-03-18 2024-02-20 Bolt Medical, Inc. Optical analyzer assembly and method for intravascular lithotripsy device
US11707323B2 (en) 2020-04-03 2023-07-25 Bolt Medical, Inc. Electrical analyzer assembly for intravascular lithotripsy device
WO2022036263A1 (fr) * 2020-08-13 2022-02-17 Cedars-Sinai Medical Center Thérapie par ultraviolets interne
US12016610B2 (en) 2020-12-11 2024-06-25 Bolt Medical, Inc. Catheter system for valvuloplasty procedure
US11672585B2 (en) 2021-01-12 2023-06-13 Bolt Medical, Inc. Balloon assembly for valvuloplasty catheter system
WO2022164879A1 (fr) * 2021-01-27 2022-08-04 Wake Forest University Health Sciences Cathéters à ballonnet à lumières multiples appropriés pour une cholangiographie d'occlusion par ballonnet et une dilatation de sphincter d'oddi et procédés d'utilisation associés
US20220273915A1 (en) * 2021-02-26 2022-09-01 Alucent Biomedical, Inc. Apparatus and methods for restoring tissue
US11648057B2 (en) 2021-05-10 2023-05-16 Bolt Medical, Inc. Optical analyzer assembly with safety shutdown system for intravascular lithotripsy device
WO2022237114A1 (fr) * 2021-05-13 2022-11-17 王雅 Cathéter à ballonnet ayant un trou latéral dans un corps principal de cathéter derrière un ballonnet
US11806075B2 (en) 2021-06-07 2023-11-07 Bolt Medical, Inc. Active alignment system and method for laser optical coupling
EP4162967A1 (fr) * 2021-10-08 2023-04-12 WeMed Technologies GmbH Système de cathéter à ballonnet
WO2023057648A1 (fr) * 2021-10-08 2023-04-13 Wemed Technologies Gmbh Système de cathéter à ballonnets
US11839391B2 (en) 2021-12-14 2023-12-12 Bolt Medical, Inc. Optical emitter housing assembly for intravascular lithotripsy device
CN114082086A (zh) * 2021-12-23 2022-02-25 赛诺神畅医疗科技有限公司 一种球囊导引导管
CN114082086B (zh) * 2021-12-23 2024-03-29 赛诺神畅医疗科技有限公司 一种球囊导引导管
CN114931695A (zh) * 2022-05-11 2022-08-23 上海玮沐医疗科技有限公司 一种带有光固化涂层的冲击波球囊导管装置
WO2024030552A1 (fr) * 2022-08-03 2024-02-08 Zeus Company Inc. Fibre optique polymère
WO2024049814A1 (fr) * 2022-08-31 2024-03-07 Medtronic, Inc. Cathéter à ballonnet multimodal comprenant un ballonnet pour lithotritie
WO2024045982A1 (fr) * 2022-09-02 2024-03-07 杭州矩正医疗科技有限公司 Cathéter à ballonnet de support de médicament et sa méthode de préparation, système de cathéter à ballonnet et méthode de génération de stent intravasculaire in situ
WO2024150193A1 (fr) * 2023-01-13 2024-07-18 Incite Medical Sarl Cathéter à ballonnet pour perfusion sélective de vaisseau latéral
WO2024158889A1 (fr) * 2023-01-27 2024-08-02 Mavericks Foundation Llc Systèmes et procédés pour retrait de ballonnet de cathéter
CN118161730A (zh) * 2024-05-13 2024-06-11 鼎科医疗技术（苏州）有限公司 一种药物球囊导管及其涂层制备方法

Also Published As

Publication number Publication date
WO2014022867A8 (fr) 2014-12-31

Similar Documents

Publication Publication Date Title
WO2014022867A1 (fr) Cathéters à ballons multiples endovasculaires à diffuseur optique pour le traitement de sténoses vasculaires
US20190321603A1 (en) Methods and systems for delivering substances into luminal walls
US6142926A (en) Radiation dose delivery catheter with reinforcing mandrel
US9114031B2 (en) Method for treating a target site in a vascular body channel
US5851171A (en) Catheter assembly for centering a radiation source within a body lumen
US20070250035A1 (en) Devices and methods for intravascular drug delivery
JP2022514982A (ja) スキャフォールディングのための装置及び方法
JP2008541835A (ja) 繊維メッシュで制御される拡張バルーンカテーテル
AU675505B2 (en) Medicament dispensing stents
US20180056086A1 (en) Percutaneous modification of vascular extracellular matrix to prevent and treat vascular restenosis
CN114616018A (zh) 用于修复组织的装置和方法
CN113646029A (zh) 用于修复组织的装置和方法
US20180344991A1 (en) Balloon catheter device for in vivo polymerization of bioresorbable scaffolds
US20120283624A1 (en) Drug Eluting Device and Method of Use Thereof
JP4746542B2 (ja) 血液の末梢保護及び治療用装置
KR20230058075A (ko) 조직 복원 장치 및 방법
WO1998030255A2 (fr) Apport intravasculaire localise de substances antioxydantes pour l'inhibition de la restenose dans des vaisseaux sanguins recanalises
WO1999040971A1 (fr) Catheter d'application de rayonnement avec capacite d'irrigation de sang
WO1999040962A1 (fr) Catheter de centrage de rayonnement avec capacite d'irrigation sanguine
CN116997382A (zh) 用于修复组织的装置和方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13752736

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13752736

Country of ref document: EP

Kind code of ref document: A1